Table 3.
Slopes from linear mixed model for estimated glomerular filtration rate (eGFR) over the course of follow-up in African American SPRINT participants by treatment group and APOL1 risk genotype
|
Group |
Time perioda | Treatment group |
APOL1 G1+G2=2 Slope (95% CI)b |
APOL1 G1+G2=0/1 Slope (95% CI)b |
APOL1 G1+G2: 2 − 0/1 Difference (95% CI) |
P value |
|---|---|---|---|---|---|---|
| All | Acute (≤6 mo) | Standard | –0.31 (–2.87, 2.26) | 0.80 (–0.46, 2.07) | –1.11 (–3.69, 1.47) | 0.398 |
| All | Acute (≤6 mo) | Intensive | –4.18 (–6.57, –1.79) | –3.53 (–4.82, –2.25) | –0.65 (–3.06, 1.77) | 0.600 |
| All | Chronic (>6 mo) | Standard | –1.13 (–2.34, 0.08) | –0.97 (–1.42, –0.52) | –0.16 (–1.45, 1.12) | 0.806 |
| All | Chronic (>6 mo) | Intensive | –1.36 (–2.46, –0.26) | –1.01 (–1.47, –0.54) | –0.35 (–1.54, 0.84) | 0.564 |
| CKD (eGFR < 60 ml/min/1.73 m2) | Acute (≤6 mo) | Standard | 0.85 (–2.22, 3.91) | 2.07 (0.48, 3.67) | –1.23 (–4.46, 2.00) | 0.457 |
| CKD (eGFR < 60 ml/min/1.73 m2) | Acute (≤6 mo) | Intensive | 0.06 (–2.93, 3.05) | –1.97 (–3.49, –0.45) | 2.03 (–1.10, 5.16) | 0.204 |
| CKD (eGFR < 60 ml/min/1.73 m2) | Chronic (>6 mo) | Standard | –1.41 (–2.50, –0.32) | –0.60 (–1.13, –0.06) | –0.81 (–2.03, 0.40) | 0.190 |
| CKD (eGFR < 60 ml/min/1.73 m2) | Chronic (>6 mo) | Intensive | –0.82 (–1.91, 0.27) | –0.75 (–1.24, –0.26) | –0.07 (–1.26, 1.12) | 0.908 |
| Non-CKD (eGFR ≥ 60 ml/min/1.73 m2) | Acute (≤6 mo) | Standard | –0.18 (–3.29, 2.93) | 0.48 (–0.98, 1.94) | –0.66 (–3.77, 2.45) | 0.679 |
| Non-CKD (eGFR ≥ 60 ml/min/1.73 m2) | Acute (≤6 mo) | Intensive | –5.44 (–8.27, –2.60) | –3.99 (–5.49, –2.48) | –1.45 (–4.31, 1.42) | 0.322 |
| Non-CKD (eGFR ≥ 60 ml/min/1.73 m2) | Chronic (>6 mo) | Standard | –1.17 (–2.71, 0.36) | –1.20 (–1.72, –0.69) | 0.03 (–1.59, 1.64) | 0.975 |
| Non-CKD (eGFR ≥ 60 ml/min/1.73 m2) | Chronic (>6 mo) | Intensive | –1.83 (–3.18, –0.49) | –1.20 (–1.75, –0.64) | –0.64 (–2.09, 0.81) | 0.388 |
CI, confidence interval; CKI, chronic kidney disease; SPRINT, Systolic Blood Pressure Intervention Trial.
a
For acute time period (≤6 mo postrandomization), slopes reflect mean change in eGFR (in ml/min/1.73 m2) over 6 mo. For chronic time period (>6 mo postrandomization), slopes reflect mean change in eGFR per 1 yr.
b
Adjusted for baseline eGFR, age, sex, history of cardiovascular disease, proportion of African admixture, and whether or not measurement occurred at a fasting study visit.